TY  - JOUR
A1  - Morbach, Caroline
A1  - Beyersdorf, Niklas
A1  - Kerkau, Thomas
A1  - Ramos, Gustavo
A1  - Sahiti, Floran
A1  - Albert, Judith
A1  - Jahns, Roland
A1  - Ertl, Georg
A1  - Angermann, Christiane E.
A1  - Frantz, Stefan
A1  - Hofmann, Ulrich
A1  - Störk, Stefan
T1  - Adaptive anti-myocardial immune response following hospitalization for acute heart failure
JF  - ESC Heart Failure
N2  - Aims

It has been hypothesized that cardiac decompensation accompanying acute heart failure (AHF) episodes generates a pro-inflammatory environment boosting an adaptive immune response against myocardial antigens, thus contributing to progression of heart failure (HF) and poor prognosis. We assessed the prevalence of anti-myocardial autoantibodies (AMyA) as biomarkers reflecting adaptive immune responses in patients admitted to the hospital for AHF, followed the change in AMyA titres for 6 months after discharge, and evaluated their prognostic utility.

Methods and results

AMyA were determined in n = 47 patients, median age 71 (quartiles 60; 80) years, 23 (49%) female, and 24 (51%) with HF with preserved ejection fraction, from blood collected at baseline (time point of hospitalization) and at 6 month follow-up (visit F6). Patients were followed for 18 months (visit F18). The prevalence of AMyA increased from baseline (n = 21, 45%) to F6 (n = 36, 77%; P < 0.001). At F6, the prevalence of AMyA was higher in patients with HF with preserved ejection fraction (n = 21, 88%) compared with patients with reduced ejection fraction (n = 14, 61%; P = 0.036). During the subsequent 12 months after F6, that is up to F18, patients with newly developed AMyA at F6 had a higher risk for the combined endpoint of death or rehospitalization for HF (hazard ratio 4.79, 95% confidence interval 1.13–20.21; P = 0.033) compared with patients with persistent or without AMyA at F6.

Conclusions

Our results support the hypothesis that AHF may induce patterns of adaptive immune responses. More studies in larger populations and well-defined patient subgroups are needed to further clarify the role of the adaptive immune system in HF progression.
KW  - adaptive immune response
KW  - acute heart failure
KW  - anti-myocardial
KW  - autoantibody
KW  - inflammation
Y1  - 2021
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-258907
VL  - 8
IS  - 4
ER  - 
TY  - JOUR
A1  - Heiling, Sven
A1  - Knutti, Nadine
A1  - Scherr, Franziska
A1  - Geiger, Jörg
A1  - Weikert, Juliane
A1  - Rose, Michael
A1  - Jahns, Roland
A1  - Ceglarek, Uta
A1  - Scherag, André
A1  - Kiehntopf, Michael
T1  - Metabolite ratios as quality indicators for pre-analytical variation in serum and EDTA plasma
JF  - Metabolites
N2  - In clinical diagnostics and research, blood samples are one of the most frequently used materials. Nevertheless, exploring the chemical composition of human plasma and serum is challenging due to the highly dynamic influence of pre-analytical variation. A prominent example is the variability in pre-centrifugation delay (time-to-centrifugation; TTC). Quality indicators (QI) reflecting sample TTC are of utmost importance in assessing sample history and resulting sample quality, which is essential for accurate diagnostics and conclusive, reproducible research. In the present study, we subjected human blood to varying TTCs at room temperature prior to processing for plasma or serum preparation. Potential sample QIs were identified by Ultra high pressure liquid chromatography tandem mass spectrometry (UHPLC-MS/MS) based metabolite profiling in samples from healthy volunteers (n = 10). Selected QIs were validated by a targeted MS/MS approach in two independent sets of samples from patients (n = 40 and n = 70). In serum, the hypoxanthine/guanosine (HG) and hypoxanthine/inosine (HI) ratios demonstrated high diagnostic performance (Sensitivity/Specificity > 80%) for the discrimination of samples with a TTC > 1 h. We identified several eicosanoids, such as 12-HETE, 15-(S)-HETE, 8-(S)-HETE, 12-oxo-HETE, (±)13-HODE and 12-(S)-HEPE as QIs for a pre-centrifugation delay > 2 h. 12-HETE, 12-oxo-HETE, 8-(S)-HETE, and 12-(S)-HEPE, and the HI- and HG-ratios could be validated in patient samples.
KW  - quality indicators
KW  - biomarker
KW  - hypoxanthine
KW  - inosine
KW  - guanosine
KW  - eicosanoids
KW  - time-to-centrifugation
KW  - pre-analytical variation
Y1  - 2021
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-246261
SN  - 2218-1989
VL  - 11
IS  - 9
ER  -